The data can be accessed via the following repository: <https://osf.io/kge7f/?view_only=8f45544cc8924d8781a1b783588c6052>.

Introduction {#sec005}
============

Multiple sclerosis is a debilitating chronic inflammatory disease that affects the central nervous system \[[@pone.0231722.ref001]\]. Relapsing-remitting multiple sclerosis (RRMS) is the most common type of multiple sclerosis (85% of cases) \[[@pone.0231722.ref002]\] and is characterised by relapses, i.e., the appearance of new symptoms or exacerbations of previous ones, followed by a period of full or partial recovery without new symptoms and progression \[[@pone.0231722.ref003]\].

Disease-modifying therapies (DMT) are used to improve the course of RRMS and reduce the severity of symptoms \[[@pone.0231722.ref004]\]. The evidence-based efficacies of all internationally approved DMT are well described in systematic reviews with network meta-analyses (NMAs) that show the superiority of alemtuzumab, natalizumab, and ocrelizumab for limiting the annualised relapse rate (ARR) compared with other DMT when considering a median follow-up time of two years \[[@pone.0231722.ref005]--[@pone.0231722.ref007]\]. However, RCTs usually have a limited duration and fail to assess long-term outcomes, which are important given the chronicity of RRMS. Other types of studies, such as observational comparative cohort studies and RCT extensions, should be considered for guiding treatment decisions. These long-term studies are methodologically poorer than RCTs, but when properly conducted, they are an important source of information about long-term safety and sustained efficacy. A recent NMA of the short- and long-term clinical outcomes of patients with clinically isolated syndrome identified that the risk of developing clinically definite multiple sclerosis was reduced after early DMT treatment compared with delayed DMT \[[@pone.0231722.ref008]\]. However, this reduction was not identified in another systematic review of long-term RRMS treatments.

Therefore, we aimed to perform a systematic review of studies reporting efficacy and safety outcomes of long-term DMT use for RRMS, compare the evidence with that derived from mid-term studies (previously published RCTs), and investigate if the published long-term data from cohort and RCTs studies are robust and reliable enough to inform clinical decision-making in RRMS.

Materials and methods {#sec006}
=====================

The systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@pone.0231722.ref009]\] (S1 Table in [S1 Appendix](#pone.0231722.s001){ref-type="supplementary-material"}) and Cochrane Collaboration recommendations \[[@pone.0231722.ref010]\], and it was registered in the International Prospective Register of Systematic Reviews (PROSPERO) with the number CRD42019123361.

Electronic searches were conducted in the PubMed and Scopus databases without any time limit or language restriction (until October 2019). Trial registration databases (ClinicalTrials.gov) and the reference lists of reviews and included studies were also searched. Complete search strategies are provided in S2 Table in [S1 Appendix](#pone.0231722.s001){ref-type="supplementary-material"}.

We included studies that fulfilled the following inclusion criteria according to the PICOS acronym:

Population {#sec007}
----------

Patients aged 18 years and older diagnosed with RRMS; studies evaluating RRMS with other forms of multiple sclerosis (i. e. clinically isolated syndrome, primary progressive multiple sclerosis or secondary progressive multiple sclerosis) were excluded.

Intervention and control {#sec008}
------------------------

DMT used as monotherapy (dose comparisons and head-to-head studies against placebo or no treatment), including ALE12/ ALE24: alemtuzumab, 12 or 24 mg/ day per 5 days and 12 months later per 3 days; BG240BID/ TID: dimethyl fumarate, 240 mg, twice-times daily or three-times daily; FING0.5QD/ 1.25QD: fingolimod, 0.5 or 1.25 mg daily; GA20QD: glatiramer acetate, 20 mg daily; IFNA22TIW/ IFNA44TIW: interferon 1a beta 22 or 44 μg three-times weekly; IFNB250EOD: interferon 1b beta, 250 μg, every other day; IFNA30QW: interferon 1a beta, 30 μg weekly; PLA: placebo.

Outcomes {#sec009}
--------

Annualised relapse rate (ARR, which is the primary outcome of most of the mid-term studies \[[@pone.0231722.ref006]\]), discontinuation due to adverse events (DAE), and the number of patients with at least one serious adverse event (SAE).

Studies {#sec010}
-------

Prospective, or retrospective comparative cohort studies, randomised phase II or later controlled trials (including post-hoc analyses), and multi- or single-arm extensions of RCTs with at least 36 months of follow-up. Equivalence studies were excluded.

For studies that evaluated a switch in therapy, we included only the arms with at least 36 months of continuing follow-up. Studies that considered at least one of the aforementioned outcomes were included.

Two researchers independently screened the titles and abstracts of the retrieved studies to identify irrelevant records. In a second stage, full-text articles were also independently evaluated by two researchers according to the inclusion and exclusion criteria. Discrepancies were reconciled in consensus meetings using a third researcher as a referee.

The following data were independently extracted by two researchers: (i) study characteristics (authors' names, year of publication, trial design, sample size, evaluated DMT, mean follow-up, diagnostic criteria, and sponsor); (ii) baseline data (patients' sex and age, disease duration, or symptoms onset); and (iii) clinical outcomes.

The baseline data and clinical outcomes of the long-term studies (≥ 36 months) were compared with those from mid-term studies (\> 3 and \< 36 months) that were recovered from a recently published systematic review \[[@pone.0231722.ref006]\]. The data were tabulated according to the ARR and standard deviation; when a study reported the confidence interval, it was converted to a standard deviation. The DAE and SAE were reported according to the number of patients with the outcome, sample size, and percentage.

The critical evaluations of the risks of bias of the studies were conducted by two independent reviewers using the Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) tool \[[@pone.0231722.ref011]\]. In the absence of consensus, points of disagreement were resolved by the opinion of a third researcher. The risks of bias of the mid-term studies were assessed using the Cochrane Collaboration revised Risk of Bias assessment tool \[[@pone.0231722.ref012]\], and the results have been published in a previous systematic review \[[@pone.0231722.ref006]\].

Results {#sec011}
=======

Our systematic review identified 1,760 records in the electronic databases after duplicate removal and obtained two by manual search. Of these, 1,699 were considered irrelevant during the screening, and 38 were excluded during the full-text appraisal ([Fig 1](#pone.0231722.g001){ref-type="fig"} and S3 Table in [S1 Appendix](#pone.0231722.s001){ref-type="supplementary-material"}). The remaining 25 records (19 studies) comprised 14 RCT, and five observational studies and were included in the qualitative synthesis (S4 Table and S7 Table in [S1 Appendix](#pone.0231722.s001){ref-type="supplementary-material"}). The articles were published between 2003 and 2018. In total, 9,018 participants (median: 147; interquartile range: 83--249) were included, and 5,468 (60%) were women (three studies did not mention the proportion of patients' genders). Five studies (26%) evaluated a switch in therapy. Altogether, 14 dosages of DMT were identified, six (32%) studies compared active therapies (head-to-head), seven (37%) compared doses, five (26%) were non-comparative, and one (5%) evaluated the active treatment against no treatment. No studies assessing natalizumab, ocrelizumab, or teriflunomide fulfilled the inclusion criteria.

![Study selection.\
The reasons are showed in supporting information.](pone.0231722.g001){#pone.0231722.g001}

A qualitative comparison of the mid- and long-term baseline data revealed they were very similar, except ATTAIN that included a population with relapses within the previous 2 years of 0.36 and 0.45 in contrast with other studies which report 2.3 or even more. The studies had follow-up times ranging from 3 to 8.5 years. The main characteristics of the studies are presented in [Table 1](#pone.0231722.t001){ref-type="table"} (additional characteristics are presented in S4 Table in [S1 Appendix](#pone.0231722.s001){ref-type="supplementary-material"}).

10.1371/journal.pone.0231722.t001

###### Characteristics of the studies included in the systematic review.

![](pone.0231722.t001){#pone.0231722.t001g}

  Study                   Year        Type of study                                              Follow-up (months)                                      Evaluated alternatives                                                                        N Participants (n Women)   Age, mean in years (SD)                                    Baseline EDSS, mean (SD)                                                                      Disease duration, mean in years (SD)
  ----------------------- ----------- ---------------------------------------------------------- ------------------------------------------------------- --------------------------------------------------------------------------------------------- -------------------------- ---------------------------------------------------------- --------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------
  **ADVANCE/ ATTAIN**     2018        RCText                                                     48                                                      PIFN125Q2W                                                                                    376 (271)                  39.0 (9.7)                                                 2.4 (1.3)                                                                                     8.5 (6.3) [^a^](#t001fn001){ref-type="table-fn"}
  PFIN125Q4W              354 (251)   38.1 (9.9)                                                 2.4 (1.4)                                               8.1 (6.1) [^a^](#t001fn001){ref-type="table-fn"}                                                                                                                                                                                                                                  
  **CARE-MS I**           2017        RCText                                                     60                                                      ALE12                                                                                         335 (NR)                   NR                                                         NR                                                                                            NR
  **CARE-MS II**          2017        RCText                                                     60                                                      ALE12                                                                                         393 (NR)                   NR                                                         NR                                                                                            NR
  **CAMMS223**            2008        RCT                                                        36                                                      IFNA44TIW                                                                                     111 (71)                   32.8 (8.8)                                                 1.9 (0.8)                                                                                     1.4 (0.2; 6.3) [^a^](#t001fn001){ref-type="table-fn"}[^b^](#t001fn002){ref-type="table-fn"}
  ALE12                   112 (72)    31.9 (8.0)                                                 1.9 (0.7)                                               1.3 (0.1; 3.5) [^a^](#t001fn001){ref-type="table-fn"}[^b^](#t001fn002){ref-type="table-fn"}                                                                                                                                                                                       
  ALE24                   110 (71)    32.2 (8.8)                                                 2.0 (0.7)                                               1.2 (0.3; 3.2) [^a^](#t001fn001){ref-type="table-fn"}[^b^](#t001fn002){ref-type="table-fn"}                                                                                                                                                                                       
  2012                    RCText      80                                                         IFNA44TIW                                               47 (30)                                                                                       33.1 (8.4)                 2.0 (0.7)                                                  1.4 (0.2; 3.1) [^a^](#t001fn001){ref-type="table-fn"}[^b^](#t001fn002){ref-type="table-fn"}   
  ALE12 and ALE24         151 (98)    31.8 (8.7)                                                 1.9 (0.8)                                               1.4 (0.1; 3.3) [^a^](#t001fn001){ref-type="table-fn"}[^b^](#t001fn002){ref-type="table-fn"}                                                                                                                                                                                       
  **CLARITY**             2017        RCText                                                     48                                                      CLA3.5                                                                                        186 (124)                  40.6 (10.5)                                                2.5 (0.0; 6.5) [^b^](#t001fn002){ref-type="table-fn"}                                         10.4 (7.1)
  **CMSSG**               1998        RCText                                                     36                                                      GA20QD                                                                                        99 (NR)                    34.7 (5.8)                                                 2.8 (1.2)                                                                                     7.4 (4.9)
  2000                    RCText      72                                                         GA20QD                                                  101 (72)                                                                                      37.5 (5.8)                 2.7 (1.6)                                                  NR                                                                                            
  2005                    RCText      96                                                         GA20QD                                                  142 (NR)                                                                                      NR                         NR                                                         NR                                                                                            
  2006                    RCText      120                                                        GA20QD                                                  232 (170)                                                                                     35.5 (6.4)                 NR                                                         8.3 (5.1)                                                                                     
  **CombiRx**             2013        RCT                                                        36                                                      IFNA30QW                                                                                      250 (173)                  37.6 (10.2)                                                2.0 (1.2)                                                                                     1.4 (4.0)
  GA20QD                  259 (185)   39.0 (9.5)                                                 1.9 (1.2)                                               1.0 (2.9)                                                                                                                                                                                                                                                                         
  **ENDORSE**             2016        RCText                                                     60                                                      BG240BID→BG240BID                                                                             501 (352)                  39.7 (9.1)                                                 2.5 (1.3)                                                                                     6.9 (5.0); 10.0 (6.5) [^a^](#t001fn001){ref-type="table-fn"}
  BG240TID→BG240TID       502 (354)   40.0 (9.1)                                                 2.4 (1.1)                                               6.4 (4.9); 9.3 (6.1) [^a^](#t001fn001){ref-type="table-fn"}                                                                                                                                                                                                                       
  PLA→BG240BID            249 (178)   39.9 (8.8)                                                 2.5 (1.1)                                               6.8 (5.3); 10.1 (6.7) [^a^](#t001fn001){ref-type="table-fn"}                                                                                                                                                                                                                      
  PLA→BG240TID            248 (166)   40.5 (9.4)                                                 2.5 (1.2)                                               7.0 (5.4); 9.5 (6.2) [^a^](#t001fn001){ref-type="table-fn"}                                                                                                                                                                                                                       
  GA20QD→BG240BID         118 (86)    38.2 (8.5)                                                 2.6 (1.2)                                               6.2 (5.0); 9.0 (5.8) [^a^](#t001fn001){ref-type="table-fn"}                                                                                                                                                                                                                       
  GA20QD→BG240TID         118 (76)    39.5 (9.5)                                                 2.7 (1.2)                                               6.3 (4.8); 9.2 (6.3) [^a^](#t001fn001){ref-type="table-fn"}                                                                                                                                                                                                                       
  **FREEDOMS**            2015        RCText                                                     48                                                      PLA→FING0.5QD                                                                                 155 (106)                  38.1 (8.3)                                                 2.4 (1.3)                                                                                     7.8 (5.9) [^a^](#t001fn001){ref-type="table-fn"}
  PLA→FING1.25QD          145 (107)   36.6 (9.2)                                                 2.4 (1.2)                                               8.4 (7.1) [^a^](#t001fn001){ref-type="table-fn"}                                                                                                                                                                                                                                  
  FING0.5QD→FING0.5QD     331 (234)   36.5 (8.6)                                                 2.3 (1.3)                                               8.0 (6.6) [^a^](#t001fn001){ref-type="table-fn"}                                                                                                                                                                                                                                  
  FING1.25QD→FING1.25QD   289 (204)   37.2 (8.9)                                                 2.4 (1.3)                                               8.2 (6.7) [^a^](#t001fn001){ref-type="table-fn"}                                                                                                                                                                                                                                  
  **GALA**                2017        RCText                                                     36                                                      GA20QD                                                                                        943 (641)                  37.4 (9.4)                                                 2.8 (1.2)                                                                                     7.7 (6.7) [^a^](#t001fn001){ref-type="table-fn"}
  **OWIMS**               2005        RCT                                                        36                                                      IFNA22TIW→IFNA22TIW                                                                           95 (NR)                    NR                                                         NR                                                                                            NR
  IFNA44TIW→IFNA44TIW     98 (NR)     NR                                                         NR                                                      NR                                                                                                                                                                                                                                                                                
  PLA→IFNA22TIW           49 (NR)     NR                                                         NR                                                      NR                                                                                                                                                                                                                                                                                
  PLA→IFNA44TIW           51 (NR)     NR                                                         NR                                                      NR                                                                                                                                                                                                                                                                                
  **PRISMS**              2005        RCText                                                     48                                                      PLA→IFNA22TIW                                                                                 189 (127)                  34.8 (29.3; 39.8) [^c^](#t001fn003){ref-type="table-fn"}   2.5 (1.2)                                                                                     5.4 (3.0; 11.2) [^c^](#t001fn003){ref-type="table-fn"}
  PLA→IFNA44TIW           184 (121)   35.6 (28.4; 41.0) [^c^](#t001fn003){ref-type="table-fn"}   2.5 (1.3)                                               6.4 (2.9; 10.3) [^c^](#t001fn003){ref-type="table-fn"}                                                                                                                                                                                                                            
  PLA→IFNA22TIW           85 (62)     35.8 (NR)                                                  3.0 (2.5)                                               NR                                                                                                                                                                                                                                                                                
  **Saida**               2017        RCText                                                     36                                                      FING0.5QD                                                                                     47 (33)                    34.9 (9.0)                                                 2.4 (1.9)                                                                                     8.2 (6.6) [^a^](#t001fn001){ref-type="table-fn"}
  FING1.25QD              46 (31)     35.7 (8.8)                                                 1.9 (1.7)                                               7.6 (5.5) [^a^](#t001fn001){ref-type="table-fn"}                                                                                                                                                                                                                                  
  **TRANSFORMS**          2015        RCText                                                     54                                                      FING0.5QD                                                                                     356 (235)                  36.5 (8.7)                                                 2.2 (1.3)                                                                                     7.3 (6.2) [^a^](#t001fn001){ref-type="table-fn"}
  **Moccia, 2018**        2018        Obs                                                        102 ^d^                                                 IFNA44TIW                                                                                     191 (123)                  31.4 (8.3)                                                 1.5 (1.0; 3.5) [^b^](#t001fn002){ref-type="table-fn"}                                         2.7 (2.8) [^a^](#t001fn001){ref-type="table-fn"}
  IFNA30QW                168 (104)   32.3 (7.8)                                                 1.5 (1.0; 3.5) [^b^](#t001fn002){ref-type="table-fn"}   2.8 (2.7) [^a^](#t001fn001){ref-type="table-fn"}                                                                                                                                                                                                                                  
  IFNB250EOD              148 (93)    34.2 (8.5)                                                 1.5 (1.0; 3.5) [^b^](#t001fn002){ref-type="table-fn"}   2.5 (2.7) [^a^](#t001fn001){ref-type="table-fn"}                                                                                                                                                                                                                                  
  **Onesti, 2003**        2003        Obs                                                        36                                                      IFNB250EOD                                                                                    83 (53)                    33.3 (7.5)                                                 1.9 (1.0)                                                                                     8.2 (6.6)
  No treatment            83 (53)     33.6 (7.6)                                                 1.9 (1.1)                                               7.3 (6.6)                                                                                                                                                                                                                                                                         
  **Patti, 2006**         2006        Obs                                                        72                                                      IFNA30QW                                                                                      62 (36)                    36.8 (7.3)                                                 NR                                                                                            5.8 (6.0)
  IFNB250EOD              64 (38)     36.6 (7.7)                                                 NR                                                      5.9 (6.3)                                                                                                                                                                                                                                                                         
  **Río, 2005**           2005        Obs                                                        60                                                      IFNB250EOD                                                                                    152 (99)                   33.2 (9.4)                                                 2.4 (1.1)                                                                                     6.1 (5.2)
  IFNA44TIW               127 (90)    35.3 (9.3)                                                 2 (0.9)                                                 6.1 (5.8)                                                                                                                                                                                                                                                                         
  IFNA30QW                103 (76)    31.3 (9.1)                                                 2 (1.1)                                                 5.1 (4.9)                                                                                                                                                                                                                                                                         
  **Ruggieri, 2003**      2003        Obs                                                        60                                                      IFNB250EOD                                                                                    56 (32)                    37 (21--52)                                                NR                                                                                            NR
  IFNA30QW                38 (24)     34 (19--50)                                                NR                                                      NR                                                                                                                                                                                                                                                                                
  IFNA22TIW               18 (12)     36 (19--48)                                                NR                                                      NR                                                                                                                                                                                                                                                                                
  IFNB250EOD→IFNA30QW     10 (6)      40 (21--50)                                                NR                                                      NR                                                                                                                                                                                                                                                                                

^a^ Symptom onset;

^b^ Median (range);

^c^ Median (interquartile range); → switch therapy. SD: standard deviation; EDSS: Expanded Disability Status Score; RCText: randomized clinical trial extension; Obs: observational study; NR: not reported. ALE12/ ALE24: alemtuzumab, 12 or 24 mg/ day per 5 days and 12 months later per 3 days; BG240BID/ TID: dimethyl fumarate, 240 mg, twice-times daily or three-times daily; FING0.5QD/ 1.25QD: fingolimod, 0.5 or 1.25 mg daily; GA20QD: glatiramer acetate, 20 mg daily; IFNA22TIW/ IFNA44TIW: interferon 1a beta 22 or 44 μg three-times weekly; IFNB250EOD: interferon 1b beta, 250 μg, every other day; IFNA30QW: interferon 1a beta, 30 μg weekly; PLA: placebo.

Additionally, 28 mid-term RCTs were considered for comparison, and their characteristics have been previously reported \[[@pone.0231722.ref006]\]. In summary, the mid-term articles were published between 1995 and 2018 with a median of 2011. Most of the studies included both treatment-naïve and treatment-experienced patients 12 (40%) or did not report this information 11 (38%), 6 (20%) included only treatment-naïve participants, and 1 (3%) assessed only treatment-experienced patients. Most of the studies had a follow-up of 2 years (median 2; interquartile range: 1--2).

The methodological qualities of the long-term studies are presented in S5 Table in [S1 Appendix](#pone.0231722.s001){ref-type="supplementary-material"}. All studies were found to have serious or critical methodological problems. The non-comparative RCT extension studies were all deemed to have critical risks of bias because the lack of a comparison group automatically precludes the comparability of such a study to an RCT (the gold standard), and the ROBINS-I questions assess comparability between groups, whether concerning baseline characteristics or concerning patient follow-up. All comparative RCT extensions and cohort studies presented with serious risks of bias, and the following domains were primarily responsible for these classifications: 'bias due to confounding factors', 'selection bias', and 'missing data bias'. Most of the studies did not report any attempt to control key confounders (e.g., adjusting the analyses), which limits the comparability between arms. Most studies only included the patients who tolerated the drug and did not discontinue the treatment during the core study into the extension phase. Many studies also lacked missing data management, which varied between 0% and 83% of the dropout rate.

The methodological qualities of the included mid-term studies were recently published \[[@pone.0231722.ref006]\]. In summary, most of the studies presented a 'low risk of bias' (58%), which was followed by 'some concerns' (25%). The domain that most frequently scored as a 'high risk of bias' was the measurement of the outcome (due to the lack of the masking of the assessors).

PIFN125Q2W, ALE12, ALE24 (unapproved dose), and CLA3.5 were the DMT with lower ARRs followed by BG240BID, BG240TID (unapproved dose), FING0.5QD, FING1.25QD (unapproved dose), GA20QD, GA40TIW, IFNA30QW, IFNB250EOD, IFNA22TIW, and IFNA44TIW. Comparison of the long- and mid-term results revealed that the ARR of the long-term studies was lower than the ARR of the mid-term studies. However, this finding lacked statistical analysis support ([Table 2](#pone.0231722.t002){ref-type="table"}).

10.1371/journal.pone.0231722.t002

###### Comparison between mid- and long-term annualised relapse rate.
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                                                   Study                                                        Mid-term (Only RCT)                                          Long-term (RCT, Extension and observational)                                                                                                                              
  ------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------ ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------
  **ALE12**                                        CARE-MS I                                                    \-                                                           0.18 (0.49) \[376\] [^a^](#t002fn001){ref-type="table-fn"}         \-                                                                                                     0.16 (NR) \[349--93%\]
  CARE-MS II                                       \-                                                           0.26 (0.63) \[426\] [^a^](#t002fn001){ref-type="table-fn"}   \-                                                                 0.21 (NR) \[357--84%\]                                                                                 
  CAMMS223                                         \-                                                           \-                                                           0.11 (0.22) \[112--100%\]                                          0.12 (0.19) \[112--100%\] [^a^](#t002fn001){ref-type="table-fn"}                                       
  CAMMS223                                         \-                                                           \-                                                           \-                                                                 0.11 (0.19) \[112--100%\] [^a^](#t002fn001){ref-type="table-fn"}                                       
  **ALE24**                                        CAMMS223                                                     \-                                                           \-                                                                 0.08 (0.19) \[110--100%\]                                                                              0.11 (0.16) \[110--100%\] [^a^](#t002fn001){ref-type="table-fn"}
  CAMMS223                                         \-                                                           \-                                                           \-                                                                 0.13 (0.19) \[110--100%\] [^a^](#t002fn001){ref-type="table-fn"}                                       
  **BG240BID**                                     CONFIRM                                                      \-                                                           0.22 (NR) \[359\]                                                  \-                                                                                                     \-
  DEFINE                                           \-                                                           0.17 (0.36) \[410\]                                          \-                                                                 \-                                                                                                     
  ENDORSE [^b^](#t002fn002){ref-type="table-fn"}   \-                                                           \-                                                           0.14 (NR) \[501--65%\]                                             0.14 (NR) \[442--57%\]                                                                                 
  ENDORSE [^b^](#t002fn002){ref-type="table-fn"}   \-                                                           \-                                                           0.14 (NR) \[468--61%\]                                             \-                                                                                                     
  ENDORSE [^b^](#t002fn002){ref-type="table-fn"}   \-                                                           \-                                                           0.11 (NR) \[192--43%\] [^d^](#t002fn004){ref-type="table-fn"}      \-                                                                                                     
  ENDORSE [^b^](#t002fn002){ref-type="table-fn"}   \-                                                           \-                                                           0.12 (NR) \[84--19%\] [^c^](#t002fn003){ref-type="table-fn"}       \-                                                                                                     
  **BG240TID**                                     CONFIRM                                                      \-                                                           0.20 (NR) \[345\]                                                  \-                                                                                                     \-
  DEFINE                                           \-                                                           0.19 (0.42) \[416\] [^a^](#t002fn001){ref-type="table-fn"}   \-                                                                 \-                                                                                                     
  ENDORSE [^b^](#t002fn002){ref-type="table-fn"}   \-                                                           \-                                                           0.16 (NR) \[502--68%)                                              0.17 (NR) \[428--58%\]                                                                                 
  ENDORSE [^b^](#t002fn002){ref-type="table-fn"}   \-                                                           \-                                                           0.20 (NR) \[461--62%)                                              \-                                                                                                     
  ENDORSE [^b^](#t002fn002){ref-type="table-fn"}   \-                                                           \-                                                           0.16 (NR) \[188--43%\] [^d^](#t002fn004){ref-type="table-fn"}      \-                                                                                                     
  ENDORSE [^b^](#t002fn002){ref-type="table-fn"}   \-                                                           \-                                                           0.12 (NR) \[76--17%\] [^c^](#t002fn003){ref-type="table-fn"}       \-                                                                                                     
  **CLA3.5**                                       CLARITY                                                      \-                                                           0.14 (0.27) \[433\] [^a^](#t002fn001){ref-type="table-fn"}         0.10 (0.24) \[186--43%\] [^a^](#t002fn001){ref-type="table-fn"}                                        \-
  **FING0.5QD**                                    Saida 2017                                                   0.50 (1.12) \[57\] [^b^](#t002fn002){ref-type="table-fn"}                                                                       0.25 (NR) \[57--100%\]                                                                                 \-
  FREEDOMS                                         \-                                                           0.18 (0.37) \[425\] [^a^](#t002fn001){ref-type="table-fn"}   0.19 (0.32) \[425--100%\] [^a^](#t002fn001){ref-type="table-fn"}   \-                                                                                                     
  FREEDOMS II                                      \-                                                           0.21 (0.39) \[358\] [^a^](#t002fn001){ref-type="table-fn"}   \-                                                                 \-                                                                                                     
  TRANSFORMS                                       0.16 (0.48) \[429\] [^a^](#t002fn001){ref-type="table-fn"}   \-                                                           0.17 (NR) \[243--57%\]                                             0.16 (NR) \[243--57%\]                                                                                 
  **FING1.25QD**                                   Saida 2017                                                   0.41 (1.03) \[54\] [^a^](#t002fn001){ref-type="table-fn"}    \-                                                                 0.21 (NR) \[54--100%)                                                                                  \-
  FREEDOMS                                         \-                                                           0.16 (0.32) \[429\] [^a^](#t002fn001){ref-type="table-fn"}   0.16 (0.32) \[429--100%\] [^a^](#t002fn001){ref-type="table-fn"}   \-                                                                                                     
  FREEDOMS II                                      \-                                                           0.20 \[370\] (0.39) [^a^](#t002fn001){ref-type="table-fn"}   \-                                                                 \-                                                                                                     
  TRANSFORMS                                       0.20 (0.52) \[420\] [^a^](#t002fn001){ref-type="table-fn"}   \-                                                           \-                                                                 \-                                                                                                     
  **GA20QD**                                       COMBIRX                                                      \-                                                           \-                                                                 0.11 (NR) \[359--100%\]                                                                                \-
  ECGA                                             0.81 (NR) \[119\]                                            \-                                                           \-                                                                 \-                                                                                                     
  CORAL                                            0.33 (0.81) \[586\]                                          \-                                                           \-                                                                 \-                                                                                                     
  BEYOND                                           \-                                                           0.34 (NR) \[448\]                                            \-                                                                 \-                                                                                                     
  Calabrese 2012                                   \-                                                           0.50 (0.40) \[48\]                                           \-                                                                 \-                                                                                                     
  CMSSG                                            \-                                                           0.59 (NR) \[125\]                                            1.34 (1.52) \[99--79%\] [^a^](#t002fn001){ref-type="table-fn"}     0.42 (0.44) \[101--81%\] [^a^](#t002fn001){ref-type="table-fn"}                                        
  CMSSG                                            \-                                                           \-                                                           \-                                                                 0.20 (NR) \[142--57%\] [^a^](#t002fn001){ref-type="table-fn"} [^e^](#t002fn005){ref-type="table-fn"}   
  CONFIRM                                          \-                                                           0.29 (NR) \[350\]                                            \-                                                                 \-                                                                                                     
  REGARD                                           \-                                                           0.29 (NR) \[378\]                                            \-                                                                 \-                                                                                                     
  GATE                                             \-                                                           0.40 (1.77) \[357\] [^d^](#t002fn004){ref-type="table-fn"}   \-                                                                 \-                                                                                                     
  **GA40TIW**                                      GALA                                                         0.33 (0.78) \[943\] [^a^](#t002fn001){ref-type="table-fn"}   \-                                                                 0.21 (NR) \[716--76%\]                                                                                 \-
  **IFNA30QW**                                     EVIDENCE                                                     0.65 (NR) \[338\]                                            \-                                                                 \-                                                                                                     \-
  TRANSFORMS                                       0.33 (0.85) \[431\] [^a^](#t002fn001){ref-type="table-fn"}   \-                                                           \-                                                                 \-                                                                                                     
  Calabrese 2012                                   \-                                                           0.50 (0.60) \[47\]                                           \-                                                                 \-                                                                                                     
  MSCRG                                            \-                                                           0.67 (NR) \[158\]                                            \-                                                                 \-                                                                                                     
  BRAVO                                            \-                                                           0.26 (0.02) \[447\]                                          \-                                                                 \-                                                                                                     
  INCOMIN                                          \-                                                           0.70 (0.90) \[92\]                                           \-                                                                 \-                                                                                                     
  COMBIRX                                          \-                                                           \-                                                           0.16 (NR) \[250--100%\]                                            \-                                                                                                     
  Río 2005 (Ob)                                    \-                                                           \-                                                           0.24 (0.51) \[89--100%\]                                           0.27 (0.56) \[37--42%\]                                                                                
  Río 2005 (Ob)                                    \-                                                           \-                                                           0.29 (0.60) \[63--71%\]                                            \-                                                                                                     
  Patti 2006 (Ob)                                  \-                                                           \-                                                           0.61 (NR) \[62--100%\]                                             0.35 (NR) \[62--100%\]                                                                                 
  Patti 2006 (Ob)                                  \-                                                           \-                                                           0.55 (NR) \[62--100%\]                                             0.32 (NR) \[62--100%\]                                                                                 
  Moccia 2018 (Ob)                                 \-                                                           \-                                                           \-                                                                 0.35 (0.43) \[168--100%\]                                                                              
  **IFNA22TIW**                                    DMSG                                                         \-                                                           0.70 (NR) \[143\]                                                  \-                                                                                                     
  PRISMS                                           \-                                                           1.82 (NR) \[189\]                                            0.80 (NR) \[167--88%\]                                             \-                                                                                                     
  OWIMS                                            \-                                                           \-                                                           0.83 (NR) \[95--100%\]                                             \-                                                                                                     
  **IFNA44TIW**                                    EVIDENCE                                                     0.54 (NR) \[339\]                                            \-                                                                 \-                                                                                                     \-
  Kappos 2011                                      0.36 (0.71) \[54\] [^a^](#t002fn001){ref-type="table-fn"}    \-                                                           \-                                                                 \-                                                                                                     
  TENERE                                           0.22 (0.81) \[104\] [^a^](#t002fn001){ref-type="table-fn"}   \-                                                           \-                                                                 \-                                                                                                     
  Calabrese 2012                                   \-                                                           0.40 (0.60) \[46\]                                           \-                                                                 \-                                                                                                     
  CARE-MS I                                        \-                                                           0.39 (1.15) \[187\] [^a^](#t002fn001){ref-type="table-fn"}   \-                                                                 \-                                                                                                     
  CARE-MS II                                       \-                                                           0.52 (0.91) \[202\] [^a^](#t002fn001){ref-type="table-fn"}   \-                                                                 \-                                                                                                     
  OPERA I                                          \-                                                           0.29 (0.62) \[411\] [^a^](#t002fn001){ref-type="table-fn"}   \-                                                                 \-                                                                                                     
  OPERA II                                         \-                                                           0.29 (0.68) \[418\] [^a^](#t002fn001){ref-type="table-fn"}   \-                                                                 \-                                                                                                     
  REGARD                                           \-                                                           0.30 (NR) \[386\]                                            \-                                                                 \-                                                                                                     
  CAMMS223                                         \-                                                           \-                                                           0.36 (0.40) \[111--100%\] ^a^                                      0.35 (0.35) \[111--100%\] [^a^](#t002fn001){ref-type="table-fn"}                                       
  CAMMS223                                         \-                                                           \-                                                           \-                                                                 0.35 (0.35) \[111--100%\] [^a^](#t002fn001){ref-type="table-fn"}                                       
  Río 2005 (Ob)                                    \-                                                           \-                                                           0.32 (0.62) \[62--100%\]                                           0.41 (0.80) \[17--27%\]                                                                                
  Río 2005 (Ob)                                    \-                                                           \-                                                           0.41 (0.72) \[46--74%\]                                            \-                                                                                                     
  OWIMS (Ob)                                       \-                                                           \-                                                           0.77 (NR) \[98--100%\]                                             \-                                                                                                     
  Moccia 2018 (Ob)                                 \-                                                           \-                                                           \-                                                                 0.32 (0.59) \[191--100%\]                                                                              
  PRISMS                                           \-                                                           1.73 \[184\] (NR)                                            0.72 (NR) \[167--91%\]                                             \-                                                                                                     
  **IFNB250EOD**                                   DMSG                                                         \-                                                           0.71 (0.67) \[158\] [^a^](#t002fn001){ref-type="table-fn"}         \-                                                                                                     \-
  INCOMIN                                          \-                                                           0.50 (0.70) \[96\] [^a^](#t002fn001){ref-type="table-fn"}    \-                                                                 \-                                                                                                     
  BEYOND                                           \-                                                           0.36 (NR) \[897\]                                            \-                                                                 \-                                                                                                     
  Río 2005 (Ob)                                    \-                                                           \-                                                           0.35 (0.61) \[134--100%\]                                          0.24 (0.48) \[114--85%\]                                                                               
  Río 2005 (Ob)                                    \-                                                           \-                                                           0.30 (0.67) \[127--95%\]                                           \-                                                                                                     
  Onesti 2003 (Ob)                                 \-                                                           \-                                                           0.40 (NR) \[83--100%\]                                             \-                                                                                                     
  Patti 2006 (Ob)                                  \-                                                           \-                                                           0.50 (NR) \[64--100%\]                                             0.45 (NR) \[64--100%\]                                                                                 
  Patti 2006 (Ob)                                  \-                                                           \-                                                           0.55 (NR) \[64--100%\]                                             0.41 (NR) \[64--100%\]                                                                                 
  Moccia 2018 (Ob)                                 \-                                                           \-                                                           \-                                                                 0.34 (0.47) \[148--100%\]                                                                              
  **PIFN125Q2W**                                   ADVANCE                                                      0.23 (NR) \[438\]                                            0.18 (NR) \[437\]                                                  0.20 (NR) \[375--86%\]                                                                                 0.06 (NR) \[185--34%)
  **PIFN125Q4W**                                   ADVANCE                                                      0.29 (NR) \[438\]                                            0.29 (NR) \[438\]                                                  0.27 (NR) \[354--81%\]                                                                                 0.12 (NR) \[170--39%\]
  ADVANCE                                          \-                                                           \-                                                           0.20 (NR) \[322--74%\]                                             \-                                                                                                     
  **No treatment**                                 Onesti 2003 (Ob)                                             \-                                                           \-                                                                 0.40 (NR) \[83--100%\]                                                                                 \-

^a^: given as confidence interval and converted to standard deviation;

^b^: ENDORSE = CONFIRM + DEFINE Extension;

^c^: switch therapy (GA → BG240) with **≥** 3-year in BG240;

^d^: switch therapy (placebo → BG240) with **≥** 3-year in BG240;

^e^: PLA and GA in original study (n = 251); ALE12/ ALE24: alemtuzumab, 12 or 24 mg/ day per 5 days and 12 months later per 3 days; BG240BID/ TID: dimethyl fumarate, 240 mg, twice-times daily or three-times daily; FING0.5QD/ 1.25QD: fingolimod, 0.5 or 1.25 mg daily; GA20QD: glatiramer acetate, 20 mg daily; IFNA22TIW/ IFNA44TIW: interferon 1a beta 22 or 44 μg three-times weekly; IFNB250EOD: interferon 1b beta, 250 μg, every other day; IFNA30QW: interferon 1a beta, 30 μg weekly; PLA: placebo; Ob: observational; NR: not reported.

The safety scenario was less consistent; the different safety profiles depended on the study, outcome evaluated (discontinuation or the number of patients with at least one serious adverse event), follow-up time, and outcome measure or report. The annual incidences of DAE and SAE were reported by 5 and 2 long-term studies, respectively, and the numbers of patients who presented with an event of DAE and SAE in the complete follow-up were reported by 8 and 9 long-term studies, respectively. The proportions of events were similar between the different treatment studies, but ALE12 and FING1.25QD (unapproved dose) exhibited reduced DAE from the mid-term to the long-term endpoints. Regarding SAE, CLA3.5 reported an increased proportion from the mid-term to the long-term (S6 Table in [S1 Appendix](#pone.0231722.s001){ref-type="supplementary-material"}).

Discussion {#sec012}
==========

We investigated the long-term effects of DMT in RRMS through a systematic review of 19 studies (9,018 participants). Recent NMAs of DMT in RRMS \[[@pone.0231722.ref005], [@pone.0231722.ref007], [@pone.0231722.ref013]\] have been limited to RCTs that have reported only short- (\< 3 months) and mid-term outcomes (\> 3 and \< 36 months). In our study, we aimed to more comprehensively summarise the clinical outcomes of DMT by expanding the follow-up to fully capture the comparative effect of long-term studies and demonstrated their limited value for supporting clinical decision-making and practice guidelines.

The comparison of mid-term RCTs (i.e., the gold-standard) with long-term RCT extensions and observational studies (i.e., real-world data) aims to identify potential differences in outcomes that could be explained by population differences. Although it would be useful to have strong evidence about the long-term outcomes of DMT, our findings highlight the importance of being cautious when considering RCT extensions and observational studies to support clinical practice because of their important limitations that can compromise the validity of their evidence. Despite these limitations, some multiple sclerosis treatment guidelines usually consider evidence extracted from mid- and long-term studies, including extension studies, to support their recommendations \[[@pone.0231722.ref014]\]. Although MS neurologists expert base their conduct on the patient's experience or personalized medicine (i.e. patient\`s needs and predictor factors) \[[@pone.0231722.ref015], [@pone.0231722.ref016]\], neurologists not expert in MS have a limited evidence to facilitate making decision, considering both clinical trials, observational studies and guidelines.

Thus far, there is no consensus regarding whether an RCT extension is an observational or an interventional study. The literature exhibits a tendency to classify these types of study as observational \[[@pone.0231722.ref017], [@pone.0231722.ref018]\] because they do not start a new therapy, and more importantly, because, except CLARITY Extension \[[@pone.0231722.ref019]\], no appropriate randomisation exists at the beginning of the extension phase. Randomisation and masking are essential characteristics that guarantee the superiority of RCTs, but they are lost during an extension phase \[[@pone.0231722.ref018], [@pone.0231722.ref020], [@pone.0231722.ref021]\]. Thus, we decided to evaluate both cohort and RCT extension studies using the ROBINS-I tool in our systematic review. Our position is in agreement with the FREEDOMS researchers who registered a RCT extension as an observational study in ClinicalTrials.gov \[[@pone.0231722.ref022]\]. Unfortunately, other RCT extension studies that were included in our systematic review were registered as interventional or only mentioned the same NCT from an original RCT \[[@pone.0231722.ref019], [@pone.0231722.ref023]--[@pone.0231722.ref029]\]. Notably, even if RCT extensions were considered interventional studies, their methodological qualities, as assessed with a tool for RCT assessment, would result in a high risk of bias classification due to the lack of randomisation, awareness of the therapy by the assessors, missing data domains, and even because comparability is lost when only one arm is followed. The number of extension studies has increased in the last decade despite the lack of standardisation of their methodological qualities, which compromises their reliabilities to inform clinical practice. The loss of randomisation is a special concern in long-term studies because the patients who enter the extension phase belong to a selected group that could tolerate \[[@pone.0231722.ref020]\] and positively respond to the therapy during the original RCT \[[@pone.0231722.ref021]\]. ATTAIN study is a good example since it is reported a frequency of relapse within the last 2 years of 0.36 and 0.45 for PIFN125Q2W and PIFN125Q4W groups, respectively, which is very below than ARR reported by other DMTs. The confounding bias domain in the ROBINS-I assesses how a study deals with a lack of randomisation by adjusting for potential confounders, which is rarely performed. In observational cohort studies, adjusting for potential confounders is more frequent, but this was not the case in the majority of the studies included in our systematic review.

Another concern due to the observational design or the extension of the clinical trial is the absence or loss of blinding patients and assessors. In the case of RRMS, the absence of blinding can be critical, since the main clinical efficacy outcomes are related to relapse, which is a subjective result, considering the range of different definitions for relapse. For example, some authors define that the relapse must last at least 24 hours \[[@pone.0231722.ref030]\], others 48 hours \[[@pone.0231722.ref031]\]; some authors define that relapse should increase ≥ 1 point in two scores of functional systems (FSS) or ≥ 2 points in an FSS \[[@pone.0231722.ref032]\], while others define relapse should increase ≥ 1 in the score of the Expanded Disability Status Scale (EDSS) if the previous EDSS score was ≤ 5.5 and ≥ 0.5 if the previous EDSS score was ≥ 6 \[[@pone.0231722.ref033]\]. Thus, these discrepancies between the definitions show how relapse can be considered a subjective outcome and, therefore, the patient or assessor awareness of the therapy can influence the assessment, contributing to different ARR results between mid- and long-term studies for the same DMT.

The lack of adjustment for covariates---as an observational study must guarantee, blinding and maintenance of randomization---as an experimental study must guarantee, may be some reasons for lower (i.e., better) ARRs reported in several of the long-term studies compared with their mid-term predecessors. For example, PRISMA presented ARRs of 1.82 for the mid-term studies and 0.83 in the long-term phase. The main reason for this unexpected decrease could be a selection bias for good responders in the long-term studies after 12% of the patients were lost between the mid- and long-term phases. In our systematic review, a quarter of the studies had a dropout rate above 20% before the beginning of the extension phase. Hemming et al. proposed the use of intention-to-treat analysis with respect to the baseline group of patients entering into a RCT; i.e., they should be treated as a responder or non-responder depending on the reason for not continuing in the extension study \[[@pone.0231722.ref034]\].

Another potential reason for discrepancies in ARR reported for the same DMT among several studies is the lack of a common adjustment: while some studies adjust the ARR for EDSS \[[@pone.0231722.ref035]\], others consider age \[[@pone.0231722.ref036]\], sex or still an unadjusted analysis \[[@pone.0231722.ref037]\]. Additionally, data can be modelled by negative binomial regression \[[@pone.0231722.ref038]\] and others by Poisson regression \[[@pone.0231722.ref039]\].

Comparing mid- and long-term results across different studies is further compromised due to the variability in the starting point (i.e., mid-term). For example, IFNA22TIW presented an ARR that ranged from 0.70 in DMSG study to 1.82 in PRISMS study, and IFNA44TIW presented an ARR lower than 0.55 for all studies; however, PRISMS reported an ARR of 1.73. This important variability in efficacy in the mid-term studies can be explained by several differences in the conduction of these studies: DMSG is a study with high risk of bias, while PRISMS is a study with low risk of bias; PRISMS is an old study that used Poser's 1983 diagnostic criteria, whereas most studies assessing IFNA44TIW used the McDonald criteria (2001 to 2010), which might have resulted in different characteristics of the included patients when the more sensitive diagnostic criteria that allow for earlier diagnosis were used \[[@pone.0231722.ref040]\]. Differences in the proportions of patients with highly active or rapidly evolving severe conditions in the mid- and long-term studies could also explain these discrepancies, but most of the mid- and long-term studies did not report this information, since the terms highly active or rapidly evolving severe RRMS have been more used only in the last decade \[[@pone.0231722.ref041], [@pone.0231722.ref042]\].

Differences in the risk of bias and population can also limit the comparability between long-term studies. For example, CARE-MS II (≥ 60 months) included only treatment-experienced patients and reported an ARR for ALE12 of 0.21, while CAMMS223 (≥ 60-month) included only treatment-naïve patients and reported an ARR for ALE12 of 0.12.

We identified a consistently higher proportion of patients with at least one SAE in the long-term compared with the mid-term studies. However, this result could be misleading because most studies did not define SAE and could consider multiple sclerosis relapses as a SAE instead of a therapeutic failure \[[@pone.0231722.ref043]\]. Another issue precluding the comparison between studies is the inconsistent manner of reporting safety outcomes. Some studies reported the annual incidence, while others reported the proportion of patients with a presenting event during the complete follow-up period. For example, CARE-MS II reported the number of patients who discontinued ALE12 each year together with the number of patients who continued ALE12 therapy each year. However, CAMMS223 reported only that five patients discontinued due to adverse events over the five years of study. For CAMMS223, the calculation of the incidence of adverse events rate is not possible. The only studies that reported safety outcomes as incidence per patient-year were CARE-MS I and II, and GALA.

One limitation of our study, as with any systematic search, is that missing studies could exist. However, a grey literature search found no additional studies, and only one additional study was found through the manual searches. These findings reinforce the quality of our search. We were unable to perform meta-analyses of the long-term outcomes because of the poor reporting of these outcomes in primary studies of DMT in RRMS.

In conclusion, the current available evidence regarding long-term safety and efficacy outcomes cannot sufficiently contribute to clinical decision making in patients with advanced RRMS because the studies have critical or serious risks of bias due to the inclusion of a selected population composed of good responders in both efficacy and safety. The conduction of high quality comparative observational studies with long-term follow-ups or RCT extensions with intention-to-treat analyses is needed to support clinical and regulatory practice. Until reliable long-term evidence is available, neurologists should continue to base their conduct on mid-term studies, patient\`s experience in terms of effectiveness and safety and, most importantly, patient\`s needs and predictor factors, according to personalized medicine.
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We would like to thank you and the reviewers for the constructive review and for the suggestions for improving our manuscript for publication in Plos One.

We send below the responses and comments to the editor and reviewers:

Editor: Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Both Reviewer\'s suggested that the manuscript should be more clinically oriented, appealing to the general neurology audience with no expertise in trial design or statistics.

Authors: We appreciate the consideration and analyze the discussion to add more clinical implications and, in addition, we add a clear recommendation to the clinician. In addition, we address other concerns highlighted by the reviewers (all changes are highlighted in blue in the text). Finally, both in the text and in the system, we have corrected institutional information about one of the authors and information about competing interests, as follows: \"RL reports personal fees from Biogen and Roche; JB reports grants and personal fees from Biogen, Novartis, Roche and Teva and personal fees from Bayer, Ipsen, Merck Serono, Sanofi, outside of the submitted work. LL, MG, RP, FFL and AW declare that they have no conflict of interest. This does not alter our adherence to PLOS ONE policies on sharing data and materials. This funder had no role in any of the study phases (ie study design, data collection, data analysis, interpretation, report writing and submission responsibility) \".

Comments to the Author

5\. Review Comments to the Author

Reviewer \#1: This a well written metanalysis of long term open label DMT studies in MS.The statistical analysis is more than adequate. The authors conclude that these studies have low quality and clinicians should not rely on them for clinical decisions. Some points to be addressed : In the abstract, the authors state that \"peginterferon, alemtuzumab, and cladribine are the most effective DMT considering ARR.:\" Since all these studies have numerous biases and since some DMTs (natalizumab, ocrelizumab and teriflounomide) were not studied in this metanalysis, this statement may be misleading to the readers and would better be avoided. In addition , it is not clearly supported in the main body of the manuscript. In fact , authors rely on tables and do not fully discuss their findings in the main text.

Authors: We fully agree with the reviewer and the abstract has been revised (excerpts from the abstract are highlighted).

Reviewer \#1: Lines 172-175 : DMTs and doses studied are presented in abbreviations that are not described in text, One has to search to the tables in order to clarify which abbreviation is which DMT. The authors should rephrase these sentences in a way that readers understand the sabstances mentioned.

Authors: We fixed it (excerpts from the methods are highlighted).

Reviewer \#1: In general, the authors empasize on findings of the programs used in this metanalysis. This makes the manuscript sound quite \" technical\" and not clinician friendly . Some recommendations for clinicians could be also added in the text.

Authors: We agree. The discussion has been revised and the changes are highlighted.

Reviewer \#2: Congratulations for your systematic review and the meaningful approach to a hot issue, such as clinical management of MS patients. I think that your work confirmed the fact that mid-term as well as long-term studies should be evaluated with criticism from the clinician perspective, because of the risk of bias that is so high lighted in your paper, though all of those \"limitations\" in comparing studies are known barriers in clinical decision making. Thus, multiple sclerosis treatment guidelines, support their recommendations based on evidence from RCTs and long term studies, as you mentioned in your paper, but they are just recommendations providing some guidance to non experts neurologists in MS, they do not substitute clinical judgement nor provide personalised medicine practice.

Authors: We fully agree with the reviewer and add that consideration to the personalized medicine in the discussion and conclusion.

Reviewer \#2: My overall impression of the paper was that it was more focused to the difficulties of achieving the aims of the study than the report of efficacy and safety outcomes. It was clear enough to me that the published longterm data are not reliable enough to inform clinical decision making, but my estimation is, that is something that is already known in the clinical setting. I would prefer the paper to be more clinical friendly-oriented and provide some light in the chaotic MS landscape.

Authors: In fact, concluding about the efficacy and safety of therapies considering the high methodological limitation of the studies is neither possible nor recommended, with the risk of suggesting that clinicians make their decisions based on the clinical findings identified here. On the other hand, we agree that some light should be given to clarify to clinicians the practical implications of these limitations. Therefore, the discussion was revised to incorporate these aspects and practical recommendations (highlighted excerpts).
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PLOS ONE

Dear Dr. Lucchetta,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by May 02 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Aristeidis H. Katsanos, MD, PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: (No Response)

Reviewer \#2: Thank you for your revision. There are some extra minor revisions that you should make. lines 52-54 needs rephrasing, lines 229-232 needs rephrasing, lines 323-325 needs rephrasing. Personalized medicine is not patient\'s experience in terms of effectiveness and safety. Please see personalized medicine in multiple sclerosis, and the definition of personalized medicine and then rephrase the lines mentioned above. All other corrections were ok

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear Aristeidis H. Katsanos,

We would like to thank you and the reviewers for the constructive review and for the suggestions for improving our manuscript for publication in Plos One.

We send below the responses and comments to the editor and reviewers:

Comments to the Author

6\. Review Comments to the Author

Reviewer \#1: (No Response)

Reviewer \#2: Thank you for your revision. There are some extra minor revisions that you should make. lines 52-54 needs rephrasing, lines 229-232 needs rephrasing, lines 323-325 needs rephrasing. Personalized medicine is not patient\'s experience in terms of effectiveness and safety. Please see personalized medicine in multiple sclerosis, and the definition of personalized medicine and then rephrase the lines mentioned above. All other corrections were ok

Authors: Thanks for the comment. We reviewed the three excerpts (highlighted), considering publications by Giovannoni 2017 and Pellegrini et al. 2019.
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Dear Dr. Lucchetta,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Aristeidis H. Katsanos, MD, PhD

Academic Editor

PLOS ONE
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Reliability in long-term clinical studies of disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review

Dear Dr. Lucchetta:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Aristeidis H. Katsanos

Academic Editor

PLOS ONE
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